Evaluation of Short-Term (1st and 3rd Month) Anthropometric Results in Obesity Patients Initiating Semaglutide Treatment: Experience of Two Tertiary Centers

Authors : Eşref Araç, İhsan Solmaz, Ömer Faruk Alakuş

Pages : 821-826

Doi:10.5798/dicletip.1841074

View : 55 | Download : 116

Publication Date : 2025-12-12

Article Type : Research Paper

Abstract :Objective: This study aimed to evaluate the weight and Body Mass Index (BMI) changes at the 1st and 3rd months in obese patients with high treatment adherence who started semaglutide treatment at two tertiary hospitals in Diyarbakır, Türkiye Methods: This retrospective cohort study included 170 patients who started semaglutide treatment, regularly attended their 1st and 3rd-month follow-ups, and did not discontinue treatment. The patients\\\' initial, 1st-month, and 3rd-month weight and BMI values were recorded. Statistical analysis was performed using the repeated measures ANOVA test. Results: The patients\\\' initial mean weight was 104.97 ± 14.53 kg, and the mean BMI was 37.07 ± 4.38 kg/m². At the end of the 3rd month of treatment, the mean weight decreased to 96.04 ± 13.92 kg, and the mean BMI decreased to 33.92 ± 4.20 kg/m². A statistically significant difference was found between the baseline, 1st-month, and 3rd-month measurements for both weight and BMI values (p<0.001). Patients lost an average of 8.51% of their initial body weight after 3 months. Conclusion: Semaglutide treatment provides a high rate of clinically significant weight loss in the short term in obese patients with high treatment adherence.
Keywords : Obezite, Semaglutid, GLP-1 Reseptör Agonistleri, Vücut Kitle İndeksi.

ORIGINAL ARTICLE URL